BACKGROUND: Biomarkers for the diagnostic classification of pancreatic cysts are urgently needed. Deregulated microRNA (miRNAs) expression is widespread in pancreatic cancer. We assessed whether aberrant miRNAs in pancreatic cyst fluid could be used as potential biomarkers for cystic precursor lesions of pancreatic cancer. METHODS: Cyst fluid specimens were prospectively collected from 40 surgically resected pancreatic cysts, and small RNAs were extracted. The 'mucinous' cohort included 14 intraductal papillary mucinous neoplasms (including 3 with an associated adenocarcinoma) and 10 mucinous cystic neoplasms; the 'nonmucinous' cohort included 11 serous cystadenomas and 5 other benign cysts. Quantitative reverse transcription PCR was performed for five miRNAs (miR-21, miR-155, miR-221, miR-17-3p, miR-191), which were previously reported as overexpressed in pancreatic adenocarcinomas. RESULTS: Significantly higher expression of miR-21, miR-221, and miR-17-3p was observed in the mucinous versus nonmucinous cysts (p < 0.01), with the mean relative fold differences being 7.0-, 7.9-, and 5.4-fold, respectively. Receiver operating characteristic curves demonstrated the highest median area under the curve for miR-21, with a median specificity of 76%, at a sensitivity of 80%. CONCLUSION: This pilot study demonstrates that profiling miRNAs in pancreatic cyst fluid samples is feasible and can yield potential biomarkers for the classification of cystic lesions of the pancreas. and IAP.
BACKGROUND: Biomarkers for the diagnostic classification of pancreatic cysts are urgently needed. Deregulated microRNA (miRNAs) expression is widespread in pancreatic cancer. We assessed whether aberrant miRNAs in pancreatic cyst fluid could be used as potential biomarkers for cystic precursor lesions of pancreatic cancer. METHODS: Cyst fluid specimens were prospectively collected from 40 surgically resected pancreatic cysts, and small RNAs were extracted. The 'mucinous' cohort included 14 intraductal papillary mucinous neoplasms (including 3 with an associated adenocarcinoma) and 10 mucinous cystic neoplasms; the 'nonmucinous' cohort included 11 serous cystadenomas and 5 other benign cysts. Quantitative reverse transcription PCR was performed for five miRNAs (miR-21, miR-155, miR-221, miR-17-3p, miR-191), which were previously reported as overexpressed in pancreatic adenocarcinomas. RESULTS: Significantly higher expression of miR-21, miR-221, and miR-17-3p was observed in the mucinous versus nonmucinous cysts (p < 0.01), with the mean relative fold differences being 7.0-, 7.9-, and 5.4-fold, respectively. Receiver operating characteristic curves demonstrated the highest median area under the curve for miR-21, with a median specificity of 76%, at a sensitivity of 80%. CONCLUSION: This pilot study demonstrates that profiling miRNAs in pancreatic cyst fluid samples is feasible and can yield potential biomarkers for the classification of cystic lesions of the pancreas. and IAP.
Authors: Jordan M Winter; John L Cameron; Keith D Lillemoe; Kurtis A Campbell; David Chang; Taylor S Riall; Joann Coleman; Patricia K Sauter; Marcia Canto; Ralph H Hruban; Richard D Schulick; Michael A Choti; Charles J Yeo Journal: Ann Surg Date: 2006-05 Impact factor: 12.969
Authors: Frank Schönleben; Wanglong Qiu; Nancy T Ciau; Daniel J Ho; Xiaojun Li; John D Allendorf; Helen E Remotti; Gloria H Su Journal: Clin Cancer Res Date: 2006-06-15 Impact factor: 12.531
Authors: Eun Joo Lee; Yuriy Gusev; Jinmai Jiang; Gerard J Nuovo; Megan R Lerner; Wendy L Frankel; Daniel L Morgan; Russell G Postier; Daniel J Brackett; Thomas D Schmittgen Journal: Int J Cancer Date: 2007-03-01 Impact factor: 7.396
Authors: A E Szafranska; T S Davison; J John; T Cannon; B Sipos; A Maghnouj; E Labourier; S A Hahn Journal: Oncogene Date: 2007-01-22 Impact factor: 9.867
Authors: Asif Khalid; Kevin M McGrath; Maliha Zahid; Matt Wilson; Debra Brody; Patricia Swalsky; Arthur J Moser; Kenneth K Lee; Adam Slivka; David C Whitcomb; Sydney Finkelstein Journal: Clin Gastroenterol Hepatol Date: 2005-10 Impact factor: 11.382
Authors: Hanno Matthaei; Dennis Wylie; Maura B Lloyd; Marco Dal Molin; Jon Kemppainen; Skye C Mayo; Christopher L Wolfgang; Richard D Schulick; Laura Langfield; Bernard F Andruss; Alex T Adai; Ralph H Hruban; Anna E Szafranska-Schwarzbach; Anirban Maitra Journal: Clin Cancer Res Date: 2012-06-21 Impact factor: 12.531
Authors: Nakul P Valsangkar; Vicente Morales-Oyarvide; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Andrew L Warshaw; Carlos Fernández-del Castillo Journal: Surgery Date: 2012-07-06 Impact factor: 3.982
Authors: Yue Zhao; Lu Zhao; Ivan Ischenko; Qi Bao; Bettina Schwarz; Hanno Nieß; Yan Wang; Andrea Renner; Josef Mysliwietz; Karl-Walter Jauch; Peter J Nelson; Joachim W Ellwart; Christiane J Bruns; Peter Camaj Journal: Target Oncol Date: 2015-02-03 Impact factor: 4.493
Authors: Rui Zhang; Bo Pang; Tao Xin; Hua Guo; Yi Xing; Shangchen Xu; Bin Feng; Bin Liu; Qi Pang Journal: Mol Neurobiol Date: 2015-01-31 Impact factor: 5.590
Authors: Katie Partyka; Mitchell McDonald; Kevin A Maupin; Randall Brand; Richard Kwon; Diane M Simeone; Peter Allen; Brian B Haab Journal: J Proteome Res Date: 2012-04-04 Impact factor: 4.466